BSE: 539528
AAYUSH WELLNESS LIMITED
Sells herbal and wellness products in India under the Aayush brand, including herbal masala positioned as a tobacco-free alternative to gutkha and dietary supplements such as Aayush Dia Shield Tablets (blood sugar management), Liver Detox Tablets, and products in immunity, brain health, and sleep categories. The company is ISO 9000 and 22000 certified. FY26 revenue from operations was Rs 15,548.20 lakhs, up 112% year-on-year from Rs 7,334.60 lakhs in FY25, with net profit of Rs 398.04 lakhs. The auditor's limited review report flagged that revenue from operations includes income from trading in shares and securities, which is not part of the core business. Q4 FY26 revenue grew 117% YoY to Rs 4,840.70 lakhs but net profit fell to Rs 56.46 lakhs from Rs 109.31 lakhs a year earlier. The visible cost items in the pack are small - employee cost at 0.3% of revenue and other opex at 1.7% - and operating cash flow turned negative at Rs (538.82) lakhs for FY26. The company has described Maharashtra's MCOCA crackdown on illegal gutkha as a potential multi-year tailwind for compliant herbal brands. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Herbal masala and wellness products, Trading in shares and securities. Small, fast-growing Indian packaged foods and wellness business with low reported margins
Exhibit 1: Financial summary, FY25–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 73 | 155 |
| EBITDA (ex other income) | 3 | 2 |
| margin % | 4.7 | 1.2 |
| Owners' profit | 0 | 4 |
| EPS, as reported (₹) | 0.69 | 0.82 |
| ROE % · ROCE % | 40.6 · 41.7 | 32.5 · 25.9 |
| Debt / equity (x) | 0.01 | 0.39 |
| Cash from operations | 0 | (5) |
| Capex | (0) | (0) |
Exhibit 2: Quarterly performance, last 6 quarters
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 26 | 22 | 23 | 40 | 45 | 48 |
| Profit before tax | 1 | 1 | 1 | 1 | 1 | 1 |
| Net profit | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS (₹) | 0.34 | 0.22 | 0.24 | 0.25 | 0.22 | 0.12 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| NESTLE INDIA LIMITED | 2,67,995 | 70.3 | 51.97 | 48.8 | 67.9 | 54.7 | — | 24.4 |
| BRITANNIA INDUSTRIES LTD | 1,20,956 | 46.4 | 23.55 | 32.4 | 49.4 | 59.8 | 7.8 | 18.0 |
| ZYDUS WELLNESS LIMITED | 16,916 | 89.9 | 2.90 | 42.1 | 3.4 | 2.4 | 16.2 | 17.1 |
| BIKAJI FOODS INTERN LTD | 14,002 | 54.2 | 8.20 | 31.0 | 14.9 | 18.3 | — | 15.3 |
| BOMBAY BURMAH TRADING COR | 10,322 | 8.0 | 1.08 | 2.9 | 26.0 | 33.5 | 7.8 | 17.7 |
| MRS BECTORS FOOD SPE LTD | 6,924 | 23.5 | 5.45 | 24.3 | 11.1 | 13.1 | 18.3 | 14.7 |
| GOPAL SNACKS LIMITED | 3,210 | 38.3 | 6.70 | — | 15.4 | 19.4 | — | 7.6 |
| ADF FOODS LIMITED | 2,941 | 32.0 | 5.14 | 20.0 | 15.7 | 18.8 | 13.1 | 18.4 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.4 | 30.8 | 20 of 40 | 51% |
| P/B | 10.0 | 3.0 | 31 of 34 | 9% |
| ROCE | 25.9 | 7.0 | 5 of 41 | 90% |
| ROE | 32.5 | 7.7 | 3 of 36 | 94% |
| Debt / Equity | 0.4 | 0.1 | 29 of 36 | 20% |
| EBITDA margin | 2.1 | 9.9 | 28 of 33 | 16% |
| Revenue growth | 116.6 | 14.1 | 6 of 36 | 86% |
| Profit growth | (48.4) | 14.1 | 29 of 33 | 13% |
| Market cap | 123 | 92 | 21 of 43 | 52% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 12 Sept 2026 · Cut-off date set as Sept 22, 2026 for e-voting at 42nd AGM | board shareholder meetings | low | — | — |
| 9 Sept 2026 · Newspaper ad filed for 42nd AGM Notice dispatch | compliance | minimal | — | — |
| 9 Sept 2026 · MD Mr. Naveenakumar Kunjaru resigns from Aayush Wellness | management changes | critical | — | — |
| 7 Sept 2026 · Aayush Wellness submits 42nd Annual Report for FY 2025-26 | compliance | medium | — | — |
| 7 Sept 2026 · Notice of 42nd AGM on September 29, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Aayush Wellness 42nd AGM set for Sept 29 via video conferencing | compliance | minimal | — | — |
| 3 Sept 2026 · Board approves 42nd AGM notice, auditor appointment, director re-appointment | board shareholder meetings | low | — | — |
| 1 Sept 2026 · BSE seeks clarification on price movement; company says no undisclosed info | regulatory legal | medium | — | — |
| 31 Aug 2026 · BSE seeks clarification on Aayush Wellness price movement | regulatory legal | high | — | — |
| 29 Aug 2026 · Aayush Wellness launches Lung Care Tablets, enters Rs 18,913 cr respiratory market | business updates | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.